Modified bone-marrow cells stop fractures in osteoporosis trial
Ten older women with osteoporosis received an infusion of their own modified bone-marrow cells in a small clinical trial. Before the treatment, participants suffered fractures every year or two, but after receiving the therapy, breaks from low-impact trauma occurred only once per decade on average. The study reported to Cell found that this one-time cell therapy sustained high efficacy for several years without side effects.